MedPath

The Methodist Hospital Research Institute

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

136

Active:6
Completed:43

Trial Phases

4 Phases

Phase 1:26
Phase 2:37
Phase 4:13
+1 more phases

Drug Approvals

2

FDA:2

Drug Approvals

Ammonia N-13

Approval Date
Dec 19, 2023
FDA

Fludeoxyglucose F18

Approval Date
Aug 13, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (118 trials with phase data)• Click on a phase to view related trials

Not Applicable
42 (35.6%)
Phase 2
37 (31.4%)
Phase 1
26 (22.0%)
Phase 4
13 (11.0%)

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Not Applicable
Not yet recruiting
Conditions
Hepatopancreaticobiliary (HPB) Malignancy
Bladder Cancer
Ovarian Cancer (OvCa)
Kidney Cancers
First Posted Date
2025-07-03
Last Posted Date
2025-07-10
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
148
Registration Number
NCT07050771

Ultrasound Evaluation for Baxter VASCU-GUARD Vascular Patches Post-Endarterectomy and Complications Assessment

Completed
Conditions
Carotid Endarterectomy (CEA) Surgical Patients
First Posted Date
2025-07-02
Last Posted Date
2025-07-02
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
500
Registration Number
NCT07048067
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

Stem Cells for Erectile Dysfunction Post RALP

Not Applicable
Not yet recruiting
Conditions
Erectile Dysfunction
Prostate Cancer
Interventions
Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR
Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office
Drug: Placebo in clinic
Drug: Placebo in the OR
First Posted Date
2025-07-02
Last Posted Date
2025-07-02
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
40
Registration Number
NCT07048314
Locations
🇺🇸

Houston Methodist, Houston, Texas, United States

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Not Applicable
Not yet recruiting
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
First Posted Date
2025-06-29
Last Posted Date
2025-07-04
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
50
Registration Number
NCT07042685
Locations
🇺🇸

Houston Methodist Neal Cancer Center, Houston, Texas, United States

Surgical Site Infection Outcomes in Natural Orifice Intracorporeal Anastomosis and Extraction (NICE) Procedure - The NICE Trial

Conditions
Diverticulitis
Surgical Site Infection
Surgical Site Infections
Colorectal Surgery
Robotic Surgical Procedures
Clinical Trials
Diverticulitis, Colonic
Diverticulitis Colon
Diverticulitis; Perforation, Bowel
First Posted Date
2025-05-04
Last Posted Date
2025-05-08
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
300
Registration Number
NCT06957236
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 28
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath